In a randomized controlled trial of hyperbaric oxygen therapy (HBOT) initiated 3 days following primary percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (STEMI), the HBOT strategy was found to be feasible and safe [1]. When compared to baseline (post-PCI) single-photon emission computed tomography (SPECT) perfusion study, the number of underperfused segments at 3 weeks was significantly reduced (47.1 ± 14.6% vs. 33.7 ± 16.2%, respectively, with p = 0.039). This significant beneficial effect was not observed in the control arm. The authors suggested a multi-center randomized clinical trial to further delineate the efficacy of immediate HBOT after primary PCI.